What matters most

Key takeaways

  • FDA clearance defines intended uses and regulatory history; it does not resolve later allegations involving tilt, perforation, fracture, or migration.
  • The JPML centralized Cook cases in October 2014, creating a coordinated pretrial proceeding rather than a recall or class action.
  • Clinical studies have examined different populations, products, and endpoints, so PREPIC2 and Cook device studies should not be treated as contradictory slogans.
  • The July 2026 JPML inventory does not provide settlement amounts, qualification criteria, or a universal retrieval deadline.

2007: Celect enters the U.S. market through 510(k)

FDA cleared the Cook Celect vena cava filter in September 2007 through the 510(k) pathway. Its described indications involved prevention of pulmonary thromboembolism in selected circumstances, including when anticoagulation was contraindicated or had failed. The device is placed in the inferior vena cava to intercept large clots before they can reach the lungs. Clearance is a regulatory marketing decision based on the submitted record; it is not a lifetime guarantee against complications and it does not decide a later product-liability claim.

Product generations matter. Cook's family includes Celect, Celect Platinum, and Günther Tulip filters, with separate regulatory records and design details. In 2017 FDA cleared Celect Platinum filter sets under K171712. An implant card, procedure report, and hospital inventory can identify the model actually used. Brand-family language is not enough to assume that evidence about one configuration applies without qualification to another.

2014: MDL 2570 is created

On October 15, 2014, the JPML centralized federal Cook IVC filter actions in the Southern District of Indiana. The transfer order identified common allegations involving filter fracture, migration, tilt, and perforation and claims about design, testing, marketing, and warnings. Coordination reduced duplicative discovery and inconsistent pretrial rulings. It did not find a defect or certify everyone with a Cook filter as a plaintiff.

The complication terms describe different findings. Tilt concerns alignment. Perforation generally describes filter components extending beyond the caval wall on imaging. Fracture means a component has broken, while migration concerns movement of a filter or fragment. Thrombosis may involve clot in the filter or vena cava. A radiology finding can be asymptomatic or clinically significant; its presence alone does not establish why it happened, whether it caused symptoms, or whether legal liability follows.

2015-2024: studies answer different clinical questions

The 2015 PREPIC2 randomized trial enrolled hospitalized patients with acute symptomatic pulmonary embolism, associated lower-limb thrombosis, and severity criteria. All received anticoagulation; adding a retrievable filter did not reduce recurrent symptomatic pulmonary embolism at three months in that studied population. The result should not be expanded to patients who cannot safely receive anticoagulation, a central indication for filters. Population and comparator define what a trial can answer.

Device-specific studies address other endpoints. A retrospective comparison reported more strut perforation with Celect than with an Option filter. A prospective Cook study published two-year results in 2024 for Celect and Günther Tulip filters and reported high technical effectiveness and retrieval success while recording adjudicated outcomes. Differences in design, enrollment, imaging follow-up, retrieval decisions, sponsorship, and endpoints mean that no single paper settles the experience of every implanted filter.

2021-2026: retrieval remains a clinical decision while the docket continues

In a 2021 announcement about a device for difficult filter removals, FDA repeated the principle from its 2014 safety communication: clinicians should consider removing a retrievable IVC filter once protection from pulmonary embolism is no longer needed. 'Consider' matters. Continuing clot risk, thrombus in the filter, embedment, penetration, anatomy, comorbidities, and procedural risk can change the balance. The statement is not a fixed removal deadline and should not prompt self-directed intervention.

JPML's July 1, 2026 report listed 6,536 actions pending in MDL 2570 and 11,473 historical actions. The federal inventory does not count every state matter or explain how each nonpending action ended. It also does not announce a global payment grid. The Southern District of Indiana's official MDL page and signed orders remain the reliable sources for procedural developments.

A personal timeline should follow the device and the clinical decision

A useful chronology records the exact filter model, placement date, access route, clinical indication, anticoagulation status, planned follow-up, and the reason the filter remained or was retrieved. Add imaging reports and, where available, images; later pulmonary embolism or deep-vein thrombosis diagnoses; symptoms; attempted retrieval reports; and any advanced procedure used for an embedded device. Dwell time is important context, not a stand-alone diagnosis.

Chest pain, shortness of breath, leg swelling, or severe abdominal or back pain can have urgent causes and need medical assessment. Litigation content cannot tell a patient whether removal is safer than continued observation. The defensible timeline keeps the categories separate: FDA cleared particular models, FDA later urged reassessment of retrievable filters, studies reported varied outcomes in defined populations, plaintiffs made contested allegations, and thousands of individual federal actions remained pending in July 2026.

Reader questions

Frequently asked questions

When was Cook IVC filter MDL 2570 created?

The JPML centralized the federal cases on October 15, 2014, in the Southern District of Indiana.

Was the MDL itself a recall?

No. An MDL coordinates civil cases. FDA clearance, safety communications, and recalls are separate regulatory processes.

Did PREPIC2 show that IVC filters never help?

No. It found no added benefit in a defined group receiving anticoagulation. It did not answer the same question for patients who cannot receive anticoagulants.

Is there one required retrieval date?

No. FDA advises considering removal once protection is no longer needed, but the decision requires individualized clinical assessment.

Primary-source file

Documents and research used

  1. The Cook Celect 510(k) record defines the device's cleared intended use and regulatory history.Cook Celect 510(k) K061815U.S. Food and Drug Administration · accessed
  2. The Cook Celect Platinum 510(k) record defines that device's cleared intended use.Cook Celect Platinum 510(k) K171712U.S. Food and Drug Administration · accessed
  3. The JPML centralized Cook IVC filter actions as MDL 2570.MDL 2570 Initial Transfer OrderU.S. Judicial Panel on Multidistrict Litigation · accessed
  4. The Southern District of Indiana's case information page is the court record for MDL 2570.MDL 2570 Case InformationU.S. District Court, Southern District of Indiana · accessed
  5. FDA's announcement concerns devices used to remove retrievable IVC filters.FDA IVC Filter Removal Device AnnouncementU.S. Food and Drug Administration · accessed
  6. The PREPIC2 randomized trial examined retrievable filters in patients with pulmonary embolism.PREPIC2 Randomized Clinical TrialPubMed / JAMA · accessed
  7. A published study reported two-year outcomes from a Cook IVC filter study.Two-Year Outcomes from the Cook IVC Filter StudyPubMed / Journal of Vascular and Interventional Radiology · accessed
  8. The JPML's July 1, 2026 report supplies the current dated federal action count for MDL 2570.Pending MDL Dockets — July 1, 2026U.S. Judicial Panel on Multidistrict Litigation · accessed